Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
United States
/
Pharmaceuticals & Biotech
Create a narrative
Arrowhead Pharmaceuticals Community
NasdaqGS:ARWR Community
1
Narratives
written by author
0
Comments
on narratives written by author
6
Fair Values set
on narratives written by author
Create a narrative
Arrowhead Pharmaceuticals
Popular
Undervalued
Overvalued
Community Investing Ideas
Arrowhead Pharmaceuticals
AN
AnalystConsensusTarget
Consensus Narrative from 14 Analysts
Plozasiran Launch Will Transition Biotech Focus Despite Regulatory Hurdles
Key Takeaways Transition to a commercial stage with plozasiran could significantly boost future revenues and improve margins through successful product launches. Early-stage obesity programs targeting new treatment pathways may create significant new revenue streams and enhance long-term growth.
View narrative
US$44.50
FV
64.6% undervalued
intrinsic discount
-13.27%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
5
users have followed this narrative
2 days ago
author updated this narrative
Your Valuation for
ARWR
ARWR
Arrowhead Pharmaceuticals
Your Fair Value
US$
Current Price
US$15.74
95.8% overvalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
-471m
545m
2015
2018
2021
2024
2025
2027
2030
Revenue US$487.6m
Earnings US$95.2m
Advanced
Set Fair Value